Pediculosis Clinical Trial
Official title:
Phase II, Multi-Center, Open-Label, Safety and Tolerance Study of a Novel Malathion Formulation in Infants and Toddlers With Pediculosis Capitis
Verified date | July 2014 |
Source | Taro Pharmaceuticals USA |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0.5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety
and tolerability of this formulation when used in children 6-24 months of age.
Status | Completed |
Enrollment | 12 |
Est. completion date | January 2012 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Months to 24 Months |
Eligibility |
Inclusion Criteria: - Confirmed active head lice infestation Exclusion Criteria: - Allergy to pediculicides or hair care products - Scalp conditions other than head lice - Previous head lice treatment within the past 4 weeks - Current antibiotic treatment |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Investigator Site | Bentonville | Arkansas |
United States | Investigator Site | Jonesboro | Arkansas |
Lead Sponsor | Collaborator |
---|---|
Taro Pharmaceuticals USA |
United States,
Meinking TL, Vicaria M, Eyerdam DH, Villar ME, Reyna S, Suarez G. A randomized, investigator-blinded, time-ranging study of the comparative efficacy of 0.5% malathion gel versus Ovide Lotion (0.5% malathion) or Nix Crème Rinse (1% permethrin) used as labe — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Participants With a Change in Cholinesterase Level at 1 Hour (Day 0). | Each patient (aged 6 - 24 months) was assessed at 1 hour (Day 0). The mean percent change (reduction) in plasma and RBC cholinesterase activity from baseline to 1 hr after application was calculated and accompanied by 95% confidence intervals. If the half-widths of the derived confidence intervals are sufficiently narrow, it will demonstrate that any observed reductions in plasma and RBC cholinesterase activity fall within established safety guidelines. Concentration of RBC-cholinesterase (RBC-ChE) and plasma cholinesterase were obtained at baseline, at 1 hr (Day 0) and at 24 hrs (Day 1) after the application of the treatment. Mean percent change (reduction) = (Post treatment value - Baseline)/ Baseline x100. |
Change from Baseline to 1 hour | Yes |
Primary | Participants With a Change in Cholinesterase Level at 24 Hrs (1 Day). | Each patient was assessed at Day 1 and the mean percent reduction in plasma and RBC cholinesterase activity from baseline to 24 hr after application was calculated and accompanied by 95% confidence intervals. Concentration of RBC-cholinesterase (RBC-ChE) and plasma cholinesterase were obtained at baseline, at 1 hr (Day 0) and at 24 hrs (Day 1) after the application of the treatment. Mean percent reduction = (Post treatment value - Baseline)/ Baseline x100. |
Change from baseline to 24 hrs (1 day) | Yes |
Primary | Participants With the Clinical Evidence of Cholinesterase Inhibition | Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence of cholinesterase inhibition. Abnormal heart rate. Diarrhea or abdominal cramps. Inappropriate sweating. Pupillary miosis (constriction). Respiratory difficulty such as chest tightness or wheezing. One participant had wheezing as medical history which continued without increase in severity throughout the treatment. |
at Baseline | Yes |
Primary | Participants With the Clinical Evidence of Cholinesterase Inhibition | Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence cholinesterase inhibition : Abnormal heart rate. Diarrhea or abdominal cramps. Inappropriate sweating. Pupillary miosis (constriction). Respiratory difficulty such as chest tightness or wheezing. One participants had wheezing as medical history which continued without increase in severity throughout the treatment. |
at 1 hr (Day 0) | Yes |
Primary | Participants With the Clinical Evidence of Cholinesterase Inhibition | Participants with any of the following symptoms of cholinesterase inhibition as numbered below were considered to have Clinical evidence of cholinesterase inhibition : Abnormal heart rate. Diarrhea or abdominal cramps. Inappropriate sweating. Pupillary miosis (constriction). Respiratory difficulty such as chest tightness or wheezing. One participants had wheezing as medical history which continued without increase in severity throughout the treatment. |
at 24 hrs (Day 1) | Yes |
Primary | Participants Clinically Cured of Head Lice 14 Days After Last Treatment | No live lice (including adults and nymphs) and nits at Day 7±1 and final lice assessment on either Day 14 (subjects not requiring retreatment) or Day 21 (for retreated subjects). | Day 7±1 and Day 14 or Day 21 | No |
Secondary | Evaluation of the Local Safety of Malathion Gel, 0.5% Based Upon Reported Adverse Events and Observed Scalp Reactions. | To evaluate the safety of Malathion Gel, 0.5% based upon reported adverse events and observed scalp reactions. Additional safety assessments included eye Irritation. | Participants were followed for a minimum of 14 days (1 treatment) and a maximum of 21 days (2 treatments) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01660321 -
Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation
|
Phase 4 | |
Completed |
NCT00545753 -
Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice
|
Phase 3 | |
Completed |
NCT00381082 -
A Randomised, Assessor-Blind, Comparative Efficacy Clinical Trial of 3 Pediculicides.
|
Phase 2/Phase 3 | |
Terminated |
NCT02499549 -
Two Treatment Regimens of Cocamide DEA Lotion for Head Lice
|
Phase 2/Phase 3 | |
Completed |
NCT05643820 -
Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis
|
Phase 1 | |
Completed |
NCT00731718 -
Control of Head Lice Infestations in Children and Adults
|
N/A | |
Not yet recruiting |
NCT01966965 -
Efficacy and Safety Study for PIOLIN® Shampoo
|
Phase 3 | |
Completed |
NCT00927407 -
Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice
|
Phase 1 | |
Completed |
NCT01518699 -
Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00207753 -
Effectiveness of Combined Albendazole and Ivermectin Treatment for Intestinal Worm Infections
|
N/A | |
Completed |
NCT00927472 -
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
|
Phase 3 | |
Completed |
NCT00963508 -
Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice
|
Phase 3 | |
Completed |
NCT01336647 -
An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
|
Phase 2 |